La Jolla Pharmaceutical Company Announces First Patient Treated in Clinical Trial of GCS-100 in Chronic Kidney Disease

La Jolla Pharmaceutical, a leader in the development of therapeutics that target galectin-3, announced it has administered the first dose for its Phase I/II clinical trial of GCS-100 in patients with chronic kidney disease. 
MarketWire